Incidence and Clinical Outcomes of Febrile Neutropenia in Adult Cancer Patients with Chemotherapy Using Korean Nationwide Health Insurance Database

Dalyong Kim1*, Soohyeon Lee2*, Taemi Youk3,4, and Soojung Hong5

1Division of Hematology & Medical Oncology, Department of Internal Medicine, Dongguk University Ilsan Hospital, Goyang; 2Division of Oncology/Hematology, Department of Internal Medicine, Korea University, Seoul; 3Department of Statistics, Korea University, Seoul; 4Research Institute, National Health Insurance Service Ilsan Hospital, Goyang; 5Division of Oncology-Hematology, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Korea.

Purpose: The aim of this study was to evaluate the episodes of febrile neutropenia (FN) in patients with gastric cancer (GC), colorectal cancer (CRC), lung cancer (LC), and breast cancer (BC); and to identify the incidence and trends of admission rates, as well as factors affecting mortality.

Materials and Methods: Using nationwide claims data, all new admissions to hospitals for FN were selected. We evaluated the incidence of FN and mortality-related clinical factors in adult cancer patients who received cytotoxic chemotherapy from January 2004 to December 2013.

Results: While the incidence of FN increased, the length of hospitalization decreased in Korea. The incidence of FN was 19.8% in LC patients, 15.5% in GC patients, 13.3% in BC patients, and 9.5% in CRC patients. The overall in-hospital mortality of FN was 12.9% and showed a decreasing trend. Admission rates to intensive care units and in-hospital mortality were the highest for lung cancer (15.2% and 19.3%, respectively). Age and sepsis syndrome were risk factors for in-hospital mortality for all cancer types.

Conclusion: Careful observation and active prophylaxis should be considered for patients at high risk of FN.

Key Words: Chemotherapy, febrile neutropenia, national health insurance

INTRODUCTION

Cancer incidence is increasing globally and in Korea. According to the annual report of cancer statistics in Korea, 37% of people are expected to develop cancer at some time in life.1 Cancer survival has been continuously improving, and the 5-year relative survival rates of all newly diagnosed cancer patients between 2011 and 2015 was 70.7%. Early detection of cancer and development of new anti-cancer drugs are important factors for improving the survival of cancer patients. Although new therapeutic options, such as targeted agents and biologics, have been introduced since 2000, most cancer patients are still treated with conventional cytotoxic chemotherapy.

Bone marrow suppression is a common adverse event of cytotoxic chemotherapy. Bone marrow suppression is a common adverse event of cytotoxic chemotherapy and induces febrile neutropenia (FN). FN is defined when the absolute neutrophil count is expected to drop to less than 500 cells/mm³ or less than 500 cells/mm³, and the body temperature is above 38.3°C or continuously above 38.0°C over a 1-hour period.2 FN can be life-threatening, and affects the schedule and dose of chemotherapy. In some patients, chemotherapy may be discontinued due to FN. Chemotherapy regimen and dose intensity are risk factors for FN. According to a review of clinical trials of...
breast cancer and non-Hodgkin’s lymphoma, hematologic toxicity data and dose-intensity data were not reported in about 40% of the studies included in that review. Also, prophylactic use of granulocyte colony stimulating factor (G-CSF) varied and was inconsistent. In addition, the degree of bone marrow suppression is very different according to the risk of each patient treated with the same chemotherapy, making it difficult to estimate the incidence of FN in the real world. Since 2014, reimbursement of long-acting G-CSF for prevention of FN has been available to some patients who have high risk of FN, but the risk factors of each patient have not been sufficiently considered for insurance coverage. Therefore, many patients still do not receive prophylactic G-CSF in Korea.

Several studies on the incidence of FN and healthcare cost have been reported in the United States, Australia, UK, and Asian countries such as Singapore and Thailand, but there is no available data in Korea. Therefore, this study aimed to evaluate the incidence of FN in patients with gastric cancer (GC), colorectal cancer (CRC), lung cancer (LC), and breast cancer (BC) who were treated with chemotherapy before prophylactic G-CSF was covered, as well as the trends for admission rates, and factors affecting mortality using the nationwide claims data from the Korean National Health Insurance Service (NHIS) database (DB). The five most commonly diagnosed types of cancer in Korea were GC, CRC, thyroid cancer, LC, BC. These four cancers, except thyroid cancer, accounted for 47% of all cancer deaths, and healthcare expenditure was higher than those for other cancers. For this reason, these four common cancers of interest were analyzed.

**MATERIALS AND METHODS**

**Data source**

In Korea, almost all citizens are covered by the NHIS as a single national insurance. As of 2013, the NHIS included 97.2% (n = 49989620) of the country’s total population, and the medical aid system included the remaining 2.8% (n = 1458871) of the population. NHIS claims data include a qualification DB, treatment DB, and clinic DB. The treatment DB contains details of treatment, type of disease, and prescriptions.

**Study population**

The subjects of this retrospective study were adult cancer patients (aged >18 years) with FN from Jan. 2004 to Dec. 2013 in the NHIS DB. Patients with newly diagnosed cancer were selected by diagnostic codes (Korean Standard Classification of Diseases based on International Classification of Diseases-10) as follows: GC (C16), CRC (C18-20), LC (C34), and BC (C50). Patients treated with chemotherapy were defined as those with anti-cancer drug classification codes after the first claims.

Since patients admitted with FN often do not receive a major diagnostic code of FN (R508) in real practice, we could not obtain appropriate data. Therefore, we used an operational definition of FN. The medical insurance system of Korea is a single-payer system. Korean doctors have no choice but to obey the insurance standards based on international guidelines, since the country does pay back the benefits if it is confirmed that treatment has not been made by the insurance coverage standards. Most patients with FN tend to be hospitalized and treated in Korea. Therefore, among cancer patients selected from the NHIS DB, patients with FN were defined as those who were hospitalized and received G-CSF and antibiotics after chemotherapy. The first FN episode after chemotherapy was selected in individual patients. We excluded patients with multiple primary cancer, Acquired Immune Deficiency Syndrome (AIDS), or hematopoietic stem cell transplants.

**Data collection and operational definition of variables**

Due to the possibility of dividing a bill for medical expenses during one hospitalization period, if the interval between requests for hospitalization was less than 7 days, it was considered as one admission based on the date of treatment commencement and termination. The following were considered to be past medical history that may affect FN if their diagnostic codes were used repeatedly for 5 years before chemotherapy initiation: diabetes (E10–E14), heart failure (I11.0, I13.0, I13.2, I15.0, I15.1, I15.9), ischemic heart disease (I20–I25), liver cirrhosis (K74, K70.4, K71.7), chronic obstructive pulmonary disease (COPD, J40-J44), and renal failure (N17–N19). Since healthcare claims data do not indicate the cancer stage, early stage and late stage were distinguished based on operation before chemotherapy. Anthracycline, taxane, platinum, and fluoropyrimidine were given priority, and a representative chemotherapeutic agent group was defined. For example, docetaxel plus adriamycin treatment was assigned to the anthracycline group, and fluorouracil plus irinotecan therapy was assigned to the fluoropyrimidine group. Hypotension (I95), shock (R57.9), septic shock (R57.2), sepsis (R65.1, A40-A41), pneumonia (J10.0, J11.0, J12-J18, J20.0, J69, J17), urinary tract infection (N39.0), candidiasis (B37), and other fungal infection (B44, B49, B59, J17.3) were considered complications of FN, and were confirmed using the claimed diagnostic code within 3 months after chemotherapy. Any code of hypotension, shock, septic shock, or sepsis was judged to be sepsis syndrome. The use of the intensive care unit (ICU) was confirmed by the existence of a claim for admission to the ICU.

**Statistical analysis**

We examined the proportion of patients with FN by gender, age, region, income, comorbidities, and operation status. If a statistical test was needed to determine whether there was a difference in the factor of interest, chi-square (or Fisher’s exact) test was performed. A logistic regression model and a Cox proportional hazard model were established to analyze the fac-
tors related to ICU treatment and in-hospital mortality in patients with FN, respectively. In the Cox proportional hazard model, the time from the occurrence of NF to death was used as the time scale. All analyses were performed using SAS v 9.4 (SAS Institute, Cary, NC, USA) and R3.1.0 (R Foundation for Statistical Computing, Vienna, Austria).

Statement of ethics
This retrospective nationwide study was reviewed and approved by the Institutional Review Board of the National Health Insurance Service Ilsan Hospital (NHIMC 2015-02-020). This study adhered to the tenets of the Declaration of Helsinki, and written informed consent was waived.

RESULTS

Characteristics of patients with febrile neutropenia
Between 2004 and 2013, a total of 759,168 patients were newly diagnosed with GC, CRC, LC, or BC. Patients without cytotoxic chemotherapy, patients with AIDS or hematopoietic stem cell transplants, and patients with multiple cancer codes were excluded from the analysis. Among 313,316 patients who received chemotherapy, 14.2% were hospitalized due to FN (Fig. 1). The overall incidence of FN was 19.8% (LC), 15.5% (GC), 13.3% (BC), and 9.5% (CRC). Baseline characteristics of inpatients with FN are shown in Table 1. The incidence of FN was the highest in patients in their 60s for GC, CRC, and LC. In patients with breast cancer, the largest proportion of FN was found in patients in their 40s (33.2%) due to the epidemiologic characteristics of the young BC population in Korea. In LC, male patients had more frequent FN (20.6% vs. 17.3%, p<0.01), but the incidence of FN was higher in female patients with GC (14.9% vs. 17%, p<0.01) and CRC (8.5% vs. 11.2%, p<0.01). LC patients had more underlying diseases, while COPD was the most common underlying disease in all cancer patients.

Hospitalization due to febrile neutropenia
The number of FN patients showed an increasing trend over the 10 years, while the incidence of FN did not (Fig. 2). The mean length of hospitalization gradually decreased (Fig. 3). Hospitalization days were longer in FN patients with LC compared to patients with other cancer types. Pneumonia was the most common complication in patients with FN (13.4–38.2%), and other complications were identified in less than 5% of patients (Table 2). ICU unit utilization was also higher in FN pa-

Fig. 1. Consort diagram for the patient selection process. AIDS, Acquired Immune Deficiency Syndrome.
Patients with LC (15.2%), followed by GC (9.4%), CRC (8.1%), and BC (5.5%). In-hospital mortality rate was 19.3% in LC, 15.1% in GC, 8.9% in CRC, and 5.9% in BC. The cost of G-CSF increased yearly (Table 3). The frequency and cost of G-CSF use were higher in FN patients with BC.

Factors related to ICU treatment and in-hospital mortality
Sepsis syndrome was the most important factor for ICU care in patients with FN (Table 4). The risk of treatment in the ICU for sepsis syndrome was 3.30 times higher in GC, 3.83 times in...
Fig. 3. Trends of mean hospitalization days for febrile neutropenia. GC, gastric cancer; CRC, colorectal cancer; LC, lung cancer; BC, breast cancer.

Table 2. Complications* in Patients with Febrile Neutropenia

|        | GC   | CRC  | LC    | BC    |
|--------|------|------|-------|-------|
| Hypotension | 14 (0.15) | 14 (0.16) | 40 (0.27) | 14 (0.12) |
| Shock   | 10 (0.11) | 2 (0.02)  | 9 (0.06)  | 3 (0.03)  |
| Septic shock | 5 (0.05)  | 2 (0.02)  | 12 (0.08) | 4 (0.04)  |
| Sepsis  | 155 (1.67) | 84 (0.95) | 285 (1.89) | 84 (0.75) |
| Pneumonia | 1243 (13.41) | 1299 (14.64) | 5753 (38.19) | 1975 (17.63) |
| Urinary tract infection | 90 (0.97)  | 133 (1.5)  | 136 (0.9)  | 137 (1.22) |
| Candidiasis | 252 (2.72) | 129 (1.45) | 458 (3.04) | 355 (3.17) |
| Aspergillosis | 7 (0.08)   | 2 (0.02)   | 19 (0.13)  | 6 (0.05)   |
| Undefined fungal infection | 3 (0.03) | 3 (0.03) | 13 (0.09) | 3 (0.03) |
| Pneumocystis | 2 (0.02) | 1 (0.01) | 5 (0.03) | 4 (0.04) |

GC, gastric cancer; CRC, colorectal cancer; LC, lung cancer; BC, breast cancer. Data are presented as n (%).

*Complications were identified using the diagnostic codes.

DISCUSSION

We used the operational definition of FN cases that were hospitalized and received G-CSF and antibiotics after chemotherapy. In other studies, using claims data, some researchers used the diagnostic code for agranulocytosis and others used the diagnostic codes for neutropenia or neutropenia with fever. Weycker suggested that FN patients can be identified in claims data with positive predictive value higher than 80% using the diagnostic codes. Although we tried to retrieve the FN cases by using the term of FN and/or agranulocytosis, we only captured a limited number of the cases. In Korea, the therapeutic use of G-CSF is covered by insurance only if the solid cancer patients treated with chemotherapy have agranulocytosis (ANC below 500 cells/mm³) or neutropenia (ANC below 1000 cells/mm³) with fever. Therefore, we searched for patients using G-CSF and antibiotics drug codes. Although the operational definition is different from previous research, we thought it would not be significantly different from the operational definitions of other studies, due to the strict standard of insurance payment in Korea.

The incidence of FN in Korean cancer patients was 14.2%, and patients with FN increased from 2004 to 2012. This increase appears to be associated with an increase in the overall number of cancer patients. Chemotherapy regimen also affected the development of FN. In patients with BC who commonly used anthracycline, the incidence of FN was higher than that in other cancer patients. With CRC, the incidence of FN increased significantly between 2005 and 2006. This was related to the rapid increase in the use of doublet chemotherapy, since 5-fluorouracil and oxaliplatin (FOLFOX) and 5-fluorouracil, irinotecan (FOLFIRI) were covered by national health insurance.
in 2006. Although it was not desirable to make a direct comparison between different study populations, the incidence of FN seemed to be higher compared to other studies. Before 2014, the prophylactic use of G-CSF was not covered by the national health insurance, which could have led to a higher incidence of FN. Weycker, et al. reported that FN occurred in 13.1% to 20.6% of patients with metastatic solid tumors during chemotherapy. Similar to our data (19.8%), FN was most frequently observed in patients with LC (20.6%). Unlike these data, the incidence of FN in non-small cell lung cancer was 6.9% in a German prospective study. In CRC, 1.8% of patients treated with adjuvant FOLFOX had FN. The incidence of FN was 5.7% to 12.3% when chemotherapy was performed in metastatic CRC patients. Notably, we reported the incidence of FN in patients with GC. There have been few articles about FN in GC due to the low incidence in Western populations, and no article on FN using claims data in Asian patients with GC. In a multicenter prospective observational study conducted in Europe, the incidence of FN in gastric cancer was 7% (14/199), whereas that in our data was 15.5%. Since chemotherapy regimens used in Europe differ from those used in East Asia, the frequency of FN might be different.

The ICU admission rate depending on cancer type ranged from 5.5% to 15.2%, whereas Australian data showed that 5.9% of the patients with solid tumor were treated for FN in the ICU. The ICU utilization rate of patients with FN in the US was higher than ours (10.1% in whole FN inpatients) as follows: 10.6% in BC, 22.9% in LC, and 19.4% in CRC. Consistent with the results of other studies, the cost of therapeutic use of G-CSF steadily increased.

The number of patients who died of FN was the highest in LC. Regardless of cancer type, old age and sepsis syndrome due to FN were risk factors of in-hospital death. In a study conducted by Dulisse, et al., sepsis was an important risk factor for FN [OR: 4.1, 95% confidence interval (CI): 2.6–6.5 in female BC; OR: 3.8, 95% CI: 3.1–4.7 in LC]. The greater the number of past

### Table 3. Use of Granulocyte-Stimulating Factors

| Year | Use of granulocyte-stimulating factors |
|------|--------------------------------------|
|      | Gastric | Colorectal | Lung | Breast |
| 2004 | 388     | 373        | 635  | 605    |
| 2005 | 880     | 658        | 1215 | 1307   |
| 2006 | 1778    | 1636       | 2463 | 2627   |
| 2007 | 2141    | 2502       | 2904 | 3674   |
| 2008 | 2296    | 2851       | 3472 | 4548   |
| 2009 | 2255    | 2800       | 3417 | 4844   |
| 2010 | 2260    | 2554       | 3829 | 5101   |
| 2011 | 2364    | 2643       | 3908 | 5572   |
| 2012 | 2365    | 2711       | 3952 | 5575   |

### Table 4. Risk Ratio of the Use of Intensive Care Unit in Cancer Patients with Febrile Neutropenia

| Factors                                  | GC          | CRC         | LC          | BC          |
|------------------------------------------|-------------|-------------|-------------|-------------|
| Female (reference: male)                 | 0.769       | 0.872       | 0.782       | 0.417       |
| Age over 65 years (reference: <65)       | 1.498       | 1.185       | 1.076       | 2.335       |
| Diabetes                                 | 1.098       | 1.068       | 1.089       | 1.301       |
| Ischemic heart disease                   | 1.178       | 1.109       | 1.098       | 1.654       |
| Liver cirrhosis                          | 1.083       | 1.229       | 1.086       | 2.844       |
| Chronic obstructive pulmonary disease    | 0.933       | 0.932       | 0.914       | 0.878       |
| Chronic kidney disease                   | 1.258       | 1.309       | 1.280       | 3.784       |
| Sepsis syndrome                          | 3.300       | 3.833       | 3.754       | 5.316       |
| Candidiasis                              | 1.102       | 0.949       | 1.268       | 0.857       |
| Pneumonia                                | 1.116       | 1.097       | 0.283       | 1.081       |
| Operation (reference: unoperated)        | 1.136       | 1.099       | 1.197       | 1.081       |

OR, odds ratio; CI, confidence interval; GC, gastric cancer; CRC, colorectal cancer; LC, lung cancer; BC, breast cancer.
Table 5. Hazard Ratio of In-Hospital Mortality in Cancer Patients with Febrile Neutropenia

| Factors                      | GC         |               | CRC         |               | LC         |               | BC         |               |
|------------------------------|------------|---------------|-------------|---------------|------------|---------------|------------|---------------|
|                              | HR         | 95% CI        | p value     | HR           | 95% CI     | p value       | HR         | 95% CI        | p value     |
| Female (reference: male)     | 0.798      | 0.692–0.920   | 0.002       | 0.815        | 0.683–0.972 | 0.023         | 0.906      | 0.811–1.012   | 0.080       | 0.389       | 0.120–1.257 | 0.116       |
| Age over 65 years (reference: <65) | 1.438     | 1.251–1.653   | <0.001      | 1.330        | 1.117–1.584 | 0.001         | 1.377      | 1.259–1.506   | <0.001      | 2.243       | 1.707–2.947 | <0.001      |
| Diabetes                     | 0.991      | 0.849–1.160   | 0.913       | 1.026        | 0.847–1.243 | 0.792         | 0.987      | 0.889–1.084   | 0.792       | 0.918       | 0.700–1.205 | 0.539       |
| Ischemic heart disease       | 1.188      | 0.973–1.450   | 0.081       | 0.985        | 0.771–1.258 | 0.906         | 0.902      | 0.809–1.006   | 0.066       | 1.555       | 1.087–2.224 | 0.016       |
| Liver cirrhosis              | 1.232      | 0.815–1.862   | 0.323       | 0.867        | 0.575–1.307 | 0.497         | 0.897      | 0.677–1.188   | 0.450       | 2.288       | 1.138–4.599 | 0.020       |
| Chronic obstructive pulmonary disease | 1.054    | 0.909–1.222   | 0.487       | 1.050        | 0.855–1.289 | 0.641         | 0.963      | 0.881–1.052   | 0.405       | 1.077       | 0.864–1.343 | 0.511       |
| Chronic kidney disease       | 0.755      | 0.447–1.275   | 0.294       | 1.381        | 0.839–2.273 | 0.205         | 1.099      | 0.858–1.408   | 0.454       | 1.434       | 0.762–2.699 | 0.265       |
| Sepsis syndrome              | 2.126      | 1.488–3.038   | <0.001      | 1.959        | 1.237–3.102 | 0.004         | 2.018      | 1.661–2.452   | <0.001      | 2.060       | 1.130–3.754 | 0.019       |
| Candidiasis                  | 1.019      | 0.619–1.681   | 0.941       | 0.461        | 0.223–0.951 | 0.037         | 0.880      | 0.688–1.125   | 0.308       | 0.700       | 0.403–1.217 | 0.206       |
| Pneumonia                    | 0.974      | 0.813–1.167   | 0.778       | 0.968        | 0.768–1.221 | 0.783         | 1.039      | 0.950–1.136   | 0.403       | 0.806       | 0.620–1.049 | 0.110       |
| Operation (reference: Unoperated) | 0.926    | 0.805–1.065   | 0.283       | 0.941        | 0.794–1.115 | 0.486         | 0.984      | 0.835–1.160   | 0.848       | 1.070       | 0.871–1.314 | 0.518       |

HR, hazard ratio; CI, confidence interval; GC, gastric cancer; CRC, colorectal cancer; LC, lung cancer; BC, breast cancer.
ORCID iDs

Dalyong Kim  https://orcid.org/0000-0003-0193-422X
Soohyeon Lee  https://orcid.org/0000-0001-9665-062X
Taemi Youk  https://orcid.org/0000-0002-4273-3777
Soojung Hong  https://orcid.org/0000-0002-4350-2794

REFERENCES

1. Hong S, Won YJ, Park YR, Jung KW, Kong HJ, Lee ES; Community of population-based regional cancer registries. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2017. Cancer Res Treat 2020;52:335-50.

2. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JJ, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011;52:e56-93.

3. Dale DC, McCarter GC, Crawford J, Lyman GH. Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. J Natl Compr Canc Netw 2003;1:440-54.

4. Schilling MB, Parks C, Deeter RG. Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: a retrospective study. Exp Ther Med 2011;2:859-66.

5. Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005;103:1916-24.

6. Chindaprasirt J, Wanitpongpun C, Limpawattana P, Thipsuthamarat K, Sripakdee W, Wirasorn K, et al. Mortality, length of stay, and cost associated with hospitalized adult cancer patients with febrile neutropenia. Asian Pac J Cancer Prev 2013;14:1115-9.

7. Kozma CM, Dickson M, Chia V, Legg J, Barron R. Trends in neutropenia-related inpatient events. J Oncol Pract 2012;8:149-55.

8. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:2258-66.

9. Lingaratnam S, Thursky KA, Slavin MA, Bennett CA, Worth LJ. The disease and economic burden of neutropenic fever in adult patients in Australian cancer treatment centres 2008: analysis of the Victorian Admitted Episodes Dataset. Intern Med J 2011;41:121-9.

10. Lingaratnam S, Worth LJ, Slavin MA, Bennett CA, Kirsa SW, Seymour JE; et al. A cost analysis of febrile neutropenia management in Australia: ambulatory v. in-hospital treatment. Aust Health Rev 2011;35:491-500.

11. Schelenz S, Giles D, Abdallah S. Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre. Ann Oncol 2012;23:1889-93.

12. Wang XJ, Wong M, Hsu LY, Chan A. Economic burden of febrile neutropenia in solid tumor and lymphoma patients: an observational study in Singapore. Value in Health 2014;17:A734.

13. Weycker D, Li X, Edelsberg J, Barron R, Kartashov A, Xu H, et al. Risk and consequences of chemotherapy-induced febrile neutropenia in patients with metastatic solid tumors. J Oncol Pract 2015;11:47-54.

14. Weycker D, Sofrygin O, Seeffeld K, Deeter RG, Legg J, Edelsberg J. Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases. BMC Health Services Research 2013;13:60.

15. Ihbe-Heffinger A, Paassens BJ, Von Schilling C, Shlaen M, Gottschalk N, Berger K, et al. Management of febrile neutropenia—a German prospective hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer, and primary breast cancer. Onkolologie 2011;34:241-6.

16. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51.

17. Goldberg RM, Sargent DJ, Morton RE; Fuchs CS, Ramanathan RK, Williamson SK, et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol 2006;24:3347-53.

18. Pinter T, Klippel Z, Cesas A, Croitoru A, Decaestecker J, Gibbs P, et al. A phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim in patients receiving first-line FOLFOX/bevacizumab or FOLFIRI/bevacizumab for locally advanced or metastatic colorectal cancer: final results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES). Clin Colorectal Cancer 2017;16:103-14.e3.

19. Kalinka-Warzocha E, Plazas JG, Mineur L, Salek T, Hendlisz A, DeCosta L, et al. Chemotherapy treatment patterns and neutropenia management in gastric cancer. Gastric Cancer 2015;18:360-7.

20. Dulisse B, Li X, Gayle JA, Barron RL, Ernst FR, Rothman KJ, et al. A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia. J Med Econ 2013;16:720-35.